Brief: CytRx Q3 loss per share $0.10

LadRx

04/11/2014 11:00

Nov 4 (Reuters) - CytRx Corp  CYTR.O : 
 * Reports 2014 third quarter financial results 
 * Q3 loss per share $0.10 
 * Says cytrx's discovery laboratory is on target to yield its first clinical 
   candidate in 2015 
 * Says initiated a global phase 2b clinical trial of aldoxorubicin for the 
   treatment of relapsed/refractory small cell lung cancer 
 
 * Source text for Eikon  ID:nPn19ytL7  
 
 * Further company coverage  CYTR.O   
 
 ((Bangalore Newsroom; +1 646 223 8780))